HER2-Positive Breast Cancer Treatment
The FDA has approved a number of targeted therapies to treat HER2-positive breast cancer, including: Trastuzumab (Herceptin) has been approved to be used to prevent a relapse in patients with early-stage HER2-positive breast cancer. Pertuzumab (Perjeta) is used to treat metastatic HER2-positive breast cancer, and also both before surgery (neoadjuvant) and after surgery (adjuvant therapy). Trastuzumab and pertuzumab together can be used […]